Answers are grounded in this paper and cite their sources.
Randomized trial shows improved efficacy of Mosun-Pola in relapsed large B-cell lymphoma, indicating a potential new treatment option.
Background Novel, accessible treatment options, are needed for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Mosunetuzumab, a T-cell–engaging bispecific antibody, plus polatuzumab vedotin, an antibody–drug conjugate, (Mosun-Pola), represents a novel fixed-duration outpatient therapy. The phase III SUNMO study (NCT05171647) demonstrated superior efficacy of Mosun-Pola versus rituximab plus gemcitabine-oxaliplatin (R-GemOx) in patients with R/R LBCL, with a manageable safety profile. We report outcomes of a Japan subgroup analysis of the SUNMO study. Methods Patients were randomized 2:1 to receive Mosun-Pola or R-GemOx. Dual primary endpoints were centrally assessed overall response rate and progression-free survival (PFS). Results At data cutoff (February 17, 2025), of 208 patients randomized (Mosun-Pola, n = 138; R-GemOx, n = 70), 16 were enrolled from Japan (Mosun-Pola, n = 9; R-GemOx, n = 7). All patients receiving Mosun-Pola achieved a response (100% [ n = 9]) versus 57.1% (n = 4/7) for those receiving R-GemOx. PFS was significantly prolonged with Mosun-Pola; median PFS of 16.2 months versus 3.8 months with R-GemOx (hazard ratio: 0.42; 95% confidence interval: 0.07–2.63). In the safety-evaluable population (Mosun-Pola, n = 9; R-GemOx, n = 7), overall incidence of adverse events was similar between the Japan subgroup and the overall population across both treatment arms. Cytokine release syndrome occurred in 5 patients who received Mosun-Pola; all events were grade 1, and all resolved. No incidence of immune effector cell-associated neurotoxicity syndrome was reported. Conclusions Mosun-Pola demonstrated promising efficacy and manageable safety in patients with R/R LBCL enrolled from Japan, which was comparable with the overall population, supporting Mosun-Pola as a potential new treatment option in this patient population. Clinical trial registration ClinicalTrials.gov, NCT05171647.
No takes yet. Share an insight, caveat, or question.
Maruyama et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: